SCHEMBL5122055

SCHEMBL5122055

COC(=O)c1ccc(CN([C@@H](C(N)=O)c2ccccc2)S(=O)(=O)c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.53
ALDH1A1 P00352 1/20 0.53
TAS2R14 Q9NYV8 4/20 0.53
BMP1 P13497 4/20 0.49
RAB9A P51151 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
MAPT P10636 2/20 0.45
ROCK2 O75116 1/20 0.45
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
PSEN1 P49768 1/20 0.43
PSEN2 P49810 1/20 0.43
APH1B Q8WW43 1/20 0.43
NCSTN Q92542 1/20 0.43
APH1A Q96BI3 1/20 0.43
PSENEN Q9NZ42 1/20 0.43
PTGES O14684 1/20 0.42
TAS2R8 Q9NYW2 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5122060 1.00 KDM4E (0.53) KDM4EALDH1A1TAS2R14BMP1RAB9A
SCHEMBL5121059 0.94 MAPT (0.54) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5121062 0.94 MAPT (0.54) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5124162 0.93 TAS2R14 (0.51) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5118026 0.93 TAS2R14 (0.64) TAS2R14BMP1MAPTPTGESTAS2R8
SCHEMBL5117413 0.93 MAPT (0.55) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5114629 0.93 PSEN1 (0.53) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5120124 0.93 BMP1 (0.56) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5117419 0.93 MAPT (0.55) KDM4EALDH1A1TAS2R14BMP1MAPT
SCHEMBL5120117 0.93 BMP1 (0.56) KDM4EALDH1A1TAS2R14BMP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1747195-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Incorporated (US) 2007-01-31 EP claimed
US-7163942-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-01-16 US claimed
WO-2005095334-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-10-13 WO claimed
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC 2005-10-06 US claimed
US-7345095-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC (US) 2008-03-18 US disclosed
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER INC 2007-06-07 US disclosed
EP-1747195-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Incorporated (US) 2007-01-31 EP disclosed
US-7163942-B2 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC. (US) 2007-01-16 US disclosed
WO-2005095334-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS INC. (US) 2005-10-13 WO disclosed
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PFIZER INC 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070129349-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PSEN1, APP, PSEN2 KDM4E 3685/4885ALDH1A1 1291/4885TAS2R14 1345/4885
US-20050222254-A1 Sulfonamide compounds for the treatment of neurodegenerative disorders PSEN1, APP, PSEN2 KDM4E 3671/4885ALDH1A1 1386/4885TAS2R14 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.